Blood Test Now Sequences Entire Fetal Genome, Avoiding Miscarriage Risk of Invasive Amniocentesis

Researchers presenting at the European Society for Human Genetics Conference in Gothenburg (June 13–16, 2026) have advanced maternal blood tests that can map a fetus's complete genome without invasive procedures. The breakthrough replaces amniocentesis—which carries a 0.1–0.5% miscarriage risk—with a single blood draw. Cost and sequencing speed have made whole-fetal-genome analysis feasible where it was merely theoretical in 2012. Clinical adoption depends on regulatory approval and whether health systems fund testing at scale.